A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus
Status:
COMPLETED
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865)